Estimulação Elétrica Transcraniana, também conhecida como Estimulação Elétrica Superficial.
A Estimulação Elétrica Transcraniana (EET – CES do original: Cranial Electrotherapy Stimulation) é uma técnica que teve início na antiga União Soviética e vem sendo utilizada desde 1950.
Trata-se de um aparelho portátil, operado por pilhas, que utiliza microcorrentes de estimulação elétrica para tratar depressão, ansiedade e Insônia com aprovação do FDA (Food and Drug Administration). Trata-se de um método com eficácia comprovada, sem efeitos colaterais e simples de ser aplicado. A EET é um tratamento realizado em casa pelo próprio paciente. As aplicações sao diárias e indolores.
Segue abaixo o resumo de um artigo publicado sobre o assunto:
A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder.
BACKGROUND: Cranial electrotherapy stimulation (CES) is a noninvasive procedure that has been used for decades in the United States to treat anxiety, depression, and insomnia in the general population. Whether CES is an effective treatment for patients with a DSM-IV diagnosis of generalized anxiety disorder (GAD) has not previously been explored.
The goal of this study was to evaluate the efficacy of CES in alleviating anxiety in patients with DSM-IV-diagnosed GAD.
METHOD: Twelve patients from 29 to 58 years of age with a DSM-IV diagnosis of GAD were enrolled from August 2005 to March 2006 through the University of California, Los Angeles (UCLA) Anxiety Disorders Program. Cranial electrotherapy stimulation treatment was administered for 6 weeks using the Alpha-Stim Stress Control System at 0.5-Hz frequency and 300-muA intensity. The primary efficacy measures were the Hamilton Rating Scale for Anxiety (HAM-A) and the Clinical Global Impressions-Improvement (CGI-I) scale.
Response to treatment was defined as a reduction of 50% or more on the HAM-A and a CGI-I score of 1 or 2 (“much improved” or “very much improved,” respectively).
RESULTS: Cranial electrotherapy stimulation was associated with a significant decrease in HAM-A scores (t = 3.083, p = .01). At endpoint, 6 patients (50% of the intent-to-treat sample and 67% of completers) had a 50% decrease in HAM-A score and a CGI-I score of 1 or 2. One additional patient significantly improved in anxiety scores but did not meet criteria for response. Adverse events were generally mild in severity, mostly consisting of headache and nausea.
CONCLUSION: This preliminary study suggests that CES may reduce symptoms of anxiety in GAD. We hope that these preliminary results will encourage further research to explore the use of CES in clinical settings.
Bystritsky A, Kerwin L, Feusner J. J Clin Psychiatry. 2008 Mar;69(3):412-7.